In a unanimous decision last month, the Supreme Court ruled that naturally occurring genes are not patentable. But, said the Court, cDNA, a man-made copy of the genetic messenger in cells, is ...

Fintel reports that on December 15, 2025, Wells Fargo maintained coverage of CareDx (NasdaqGM:CDNA) with a Equal-Weight ...

In a unanimous ruling yesterday, the Supreme Court held that patenting a gene violates Section 101 of the Patent Act. Though Myriad Genetics had indeed made “new and useful” discoveries, these fell ...

Although qRT-PCR studies provide valuable information about the relative expression of transcripts in a cell, they are difficult to perform with very small numbers of cells (for example, 1–1,000 cells ...

CDNA is 12 months away from scaling up in a big way via licensing agreements being monetized. CDNA is growing the top-line at low to mid 20% rates Q/Q while being able to hold its operating expenses ...

This article first appeared on GuruFocus. CareDx Inc (NASDAQ:CDNA) is set to release its Q3 2025 earnings on Nov 4, 2025. The consensus estimate for Q3 2025 revenue is $95.25 million, and the earnings ...

Nadex has announced a major operational transition as part of a broader strategic effort to streamline its product development cycle and deliver a more modern ...

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). We reversed our stance ...

CareDx Inc (NASDAQ:CDNA) is set to release its Q2 2025 earnings on Aug 6, 2025. The consensus estimate for Q2 2025 revenue is $90.56 million, and the earnings are expected to come in at -$0.10 per ...